Cardiac pathology of fatal trastuzumab therapy [3]

Journal of Clinical Pathology

Volumn 61, Issue 1, 2008, Pages 143-144

  Suvarna, S K ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIRUBICIN; HORMONE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ASCITES; AUTOPSY; BREAST TUMOR; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; HEART ARREST; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; JAUNDICE; LETTER; LIVER METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; PRIORITY JOURNAL; SPINE METASTASIS; CHEMICALLY INDUCED DISORDER; FATALITY; HEART MUSCLE CELL; MIDDLE AGED; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FATAL OUTCOME; FEMALE; HEART ARREST; HUMANS; MIDDLE AGED; MYOCYTES, CARDIAC;

EID: 38449119650     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.047464     Document Type: Letter

References (5)

1. Routledge HC, Rea DW, Steeds RP. Monitoring the introduction of new drugs - Herceptin to cardiotoxicity. Clin Med 2006;6:78-81.
2. Levine MN. Tristuzumab cardiac side effects: only time will tell. J Clin Oncol 2005;23:7775-6.
3. Keefe DL. Trastuzumab-associated cardiac toxicity. Cancer 2002;95:1592-600.
4. Lewis W, Silver MD. Adverse effects of drugs on the cardiovascular system. In: Silver MD, Gotlieb AI, Schoen FJ, eds. Cardiovascular Pathology. 3rd edn. New York: Churchill Livingstone, 2001:541-61.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.